LDS/Medical Tests/E6 and E7 Gene Expression Detection Assay for Cervical Cancer (HPV OncoTect, QuantiVirus™)

E6 and E7 Gene Expression Detection Assay for Cervical Cancer (HPV OncoTect, QuantiVirus™)

HPV is one of the most common sexually transmitted infections and a necessary cause of cervical cancer. HPV is a member of the papilloma virus family, which contains more than 200 different HPV types. HPV causes a wide range of infections, including common and genital warts, and genital and anal cancers. HPV normally causes a transient, benign infection. It is medically significant, however, due to its strong association with cervical cancer, with >99% of cervical cancers associated with HPV infection.

While HPV is the major cause of cervical cancer, not everyone who is infected with HPV will develop the disease. Ninety five percent of HPV positive individuals will spontaneously clear the disease without further problems.

Only in a small number of infected women with oncogenic types of HPV willprogress to high-grade lesions or even cervical cancer if not treated for disease.In persistent infections, HPV virus has the ability to integrate part of its genome into the host chromosome, most likely leading to cancer. Several genes are integrated during this process; the most common are E6 and E7, which are known as being oncogenic.

Overexpression of E6 and E7 leads to transformation and cell immortalization or malignant transformation leading to cancer. Several molecular assays are available for detection of E6 and E7 gene expression from endocervical epithelial cells. One of the most used diagnostic tests is HPV OncoTect™. This is a flow cytometry-based in situ test for the detection of HPV E6 and E7 mRNA in intact ectocervical cells. HPV OncoTect™ takes advantage of the fact that oncogenic genotypes of HPV overexpress E6 and E7 mRNA following integration of HPV into genomic DNA. Many studies have demonstrated that detection of active viral mRNA by this assay might directly correlate with morphologic changes in cervical cells signifying cervical cancer.

  • Screening for early cervical cancer detection
  • As an aid in diagnosis of cervical cancer
  • Treatment and management of cervical cancer

Detection of E6 and E7 mRNA indicates cellular transformation and the possible presence of cancerous transformation of ≥ CIN2. Treatment and/or close clinical follow-up is recommended.

Expressed in:

  • Cervical intraepithelial neoplasia (CIN2 and over)

Can be expressed in other intraepithelial lesions such as:

  • Atypical Squamous Cells of Undetermined Significance (ASCUS)
  • Atypical Squamous Cells, Cannot Exclude High Grade Intraepithelial Lesion (ASC-H):
  • Low Grade Squamous Intraepithelial Lesion (LSIL)
  • High Grade Squamous Intraepithelial Lesion (HSIL)
  • Squamous Cell Carcinoma (SCC)
  • Adenocarcinomas

Not Detected (Negative for E6/E7 mRNA)

RNA hybridization detected by flow cytometry. Other molecular methods include; RNA detection by FISH, RNA expression by Real-PCR.

Cells from the cervix are collected using a brush or spatula in liquid cytology media ThinPrep or SurePath.

Specimens can be also collected using swab and transport in viral transport media or any molecular media. Biopsy can be also used, however, cells must be separate using protease for detection by flow cytometry.

Stability

  • ThinPrep and SurePath specimens are stable up to 21 days
  • Viral transport media are stable up to 7 days
Papanicolaou test (Pap test), HPV genotyping, P16 by IHC, Colposcopy, Biopsy, Chlamydia and Neisseria by Nucleic acid amplification (PCR, TMA, SDA), chromosomal abnormality by FISH.
2-5 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login